Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.34 - $4.73 $93,132 - $188,254
-39,800 Reduced 40.32%
58,900 $151,000
Q1 2024

May 15, 2024

SELL
$4.65 - $9.31 $320,850 - $642,390
-69,000 Reduced 41.14%
98,700 $485,000
Q4 2023

Feb 14, 2024

BUY
$5.81 - $11.2 $220,779 - $425,600
38,000 Added 29.3%
167,700 $1.47 Million
Q3 2023

Nov 14, 2023

BUY
$11.47 - $25.07 $95,201 - $208,081
8,300 Added 6.84%
129,700 $1.49 Million
Q2 2023

Aug 14, 2023

SELL
$24.7 - $37.61 $526,110 - $801,093
-21,300 Reduced 14.93%
121,400 $3.07 Million
Q1 2023

May 15, 2023

BUY
$18.36 - $35.27 $132,192 - $253,944
7,200 Added 5.31%
142,700 $4.6 Million
Q4 2022

Feb 14, 2023

SELL
$18.32 - $30.66 $5.69 Million - $9.52 Million
-310,600 Reduced 69.63%
135,500 $2.5 Million
Q3 2022

Nov 14, 2022

BUY
$14.33 - $28.47 $5.27 Million - $10.5 Million
368,000 Added 471.19%
446,100 $12 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.